Phase 2 N=74 Intensive Glycemic Control for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=74 Glycemic Control and Variability for Congestive Heart Failure Exacerbation
Congestive Heart Failure · Diabetes Mellitus
Primary: Hospital Length of Stay — 7; 8 days
N/A N=34 Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
N/A N=13 Dark Chocolate and Glucose Levels in Diabetes
Type 2 Diabetes · Type 1 Diabetes
Primary: Blood Glucose Incremental Area Under the Curve — 240.5; 83.81 mM x 120 minutes
N/A N=187 Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation
Type 2 Diabetes Mellitus · Colonoscopy
Primary: Abnormal Glucose Levels After Colonoscopic Preparation — 2; 0; 185 Participants
N/A N=60 Hyperglycemia in Renal Transplantation
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
N/A N=21 Procoagulant Effects of Hyperglycemia After Acute Stroke: A Pilot Study
Ischemic Stroke · Hyperglycemia
Primary: FVIIa — 69.7; 124.4 mU/ml
N/A N=300 Prevalence of Inpatient Hyperglycemia: Risks, Complications and Outcomes
Diabetes Mellitus · Diabetes Complications
Primary: Prevalence of Hyperglycemia in the Elective Orthopedic Population — 140 patients
Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=27 Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes
Diabetes Mellitus, Type II · Hypoglycemia · Cognitive Change
Primary: Psychomotor Speed — 48.7; 56.6 score on a scale
Early Phase 1 N=15 Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults
Vascular Stiffness · Insulin Sensitivity
Primary: Change in Flow Mediated Dilation (FMD) Between Baseline and After 2 Hour Insulin Clamp — 11.8; 11.8; 8.9; 8.95 % change
N/A N=130 Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia
Hyperglycemias
Primary: Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours — 13.0; 22.5 hours
N/A N=253 Avoidance of Hyperglycaemia in People With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Hyperglycaemia Avoidance Scale — 44.6 score on a scale
N/A N=14 The Effect of Hypoxia on Type 2 Diabetes and Weight Loss
Type2 Diabetes
Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1
N/A N=12 How Common is Hypoglycaemia in Older People With Diabetes Who Fall?
Diabetes · Hypoglycaemia
Primary: Proportion of Participants With Captured Hypoglycaemia — 3 Participants
N/A N=101 The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes
Diabetes Mellitus, Type 2 · Medication Adherence · HYPERGLYCEMIA
Primary: Hemoglobin A1C at 4 Weeks — 10.5; 11.1 percentage of glycosylated hemoglobin
N/A N=11 Hypoglycemia (Low Blood Sugar) and the Heart
Hypoglycemia · Type 2 Diabetes
Primary: Number of Participants With Hypoglycemia (Blood Sugar Level <70 mg/dl — 11 Participants
N/A N=35 Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery
Type 2 Diabetes Mellitus · Obesity
Primary: Percentage of Patients With Type 2 Diabetes Mellitus Who Achieve Fasting Blood Glucose of Less Than 5.6 mmol/l and/or HbA1c of Less Than 6% — 4; 4 Participants
N/A N=20 To Bathe or Not to Bathe
Diabetes Mellitus, Type 2
Primary: Mean AUC (Area Under the Curve) Plasma [Glucose] — 1677; 1797; 1662 AU
Phase 4 N=23 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Non-Insulin-Dependent Diabetes Mellitus
Primary: Duration of Hyperglycaemia (>126 mg/dL) in Hours at Baseline Compared to After 12 Weeks on Treatment — 17.31; 17.53; 15.30; 10.83 Hours — p=0.064
Early Phase 1 N=20 Metabolic Causes of Thrombosis in Type 2 Diabetes - Question 4
Type 2 Diabetes
Primary: Percent Changes in Endothelial Function as Measured by Flow Mediated Dilation by 2D Doppler Ultrasound on Day 2 — 2; 7 percentage of change
Phase 1 N=22 Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans
Insulin Resistance, Diabetes
Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146
N/A N=170 TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients
Hyperglycemia
Primary: Mortality — 36 mortality rate
N/A N=16 Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices, a Pilot Study.
Diabetes Mellitus
Primary: Percentage of Time Spent in Hyperglycemia > 180 mg/dL — 35.47; 35.25 percentage of time spent > 180mg/dL
N/A N=14 Impact of Hypoglycaemia in Patients With Diabetes Mellitus Type 2 on Platelet Activation
Diabetes Mellitus With Hypoglycemia · Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP
N/A N=30 QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia
Diabetes Related Complications
Primary: Change in the Corrected QT-interval During Nocturnal Hypoglycemia — 3; 5 Participants
N/A N=86 Stop Emergency Room Visits for Hyperglycemia Project - District of Columbia (DC)
Type 2 Diabetes Mellitus
Primary: Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit — 0 events
Phase 2 N=60 BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes
Pre-Diabetes
Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57
Phase 4 N=37 The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35